TS
MRNS

Thomas Steyer’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Thomas Steyer’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-223,750
Closed -$7.3M – 101
2017
Q4 		$7.3M Sell
223,750
-68,750
-24% -$1.85M 0.06% 72
2017
Q3 		$6.87M Buy
+292,500
New +$3.28M 0.06% 75

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Thomas Steyer's MRNS Position: Q1 2018 in Review

Thomas Steyer sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2018, closing a stake of 223,750 shares — an estimated $7.3M sold.

Thomas Steyer first reported a position in MRNS in Q3 2017 and held it in 2 quarters. The position peaked at $7.3M in Q4 2017. 60 funds tracked by Wall St. Rank hold MRNS as of Q1 2018.

  • Thomas Steyer reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • Thomas Steyer sold 223,750 Marinus Pharmaceuticals, Inc shares in Q1 2018, an estimated $7.3M.
  • Thomas Steyer first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 2 quarters.
  • Thomas Steyer's Marinus Pharmaceuticals, Inc position peaked at $7.3M in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2018.

Based on Farallon Capital Management's 13F filing for Q1 2018, filed 15 May 2018.